DaVita Inc. will pay $690 million for DSI Renal Inc. in a deal expected to close by the third quarter.
“We look forward to joining the dedicated teammates and physicians associated with DSI in continuing to provide quality care to ESRD patients,” said Kent Thiry, DaVita’s chairman and CEO. “This acquisition introduces us to several new geographies and makes us a more effective competitor in selected areas.”
Completion of the transaction is subject to customary closing conditions including Hart-Scott-Rodino antitrust clearance. DaVita anticipates that the company will have to divest some centers as a condition of the transaction.
DSI currently operates 106 dialysis centers serving approximately 8,000 patients. Its annual revenue is about $360 million.
